Opening: Real consultation scenario
In a reproductive clinic, a 35-year-old woman presents with her hormone panel and AMH report: FSH 38 IU/L, AMH 0.2 ng/mL, and ultrasound showing a total of 2 antral follicles in both ovaries. She has been amenorrheic for 4 months and wants to confirm one thing: In China, can I still undergo IVF with premature ovarian insufficiency?
I. Can IVF Be Done with Premature Ovarian Insufficiency: Direct Answer
Yes, but the approach depends entirely on the specific stage of ovarian decline and residual reserve. Clinically, Premature Ovarian Insufficiency (POI) is divided into two categories:
- Type with residual follicular activity (about 15%-25% of POI patients): AMH between 0.2-0.8 ng/mL, FSH fluctuating between 25-40 IU/L, with occasional ovulation or menstruation. These patients can attempt autologous IVF but must use a natural cycle or mild stimulation protocol, typically yielding 1-3 oocytes per cycle.
- Type with complete ovarian failure: AMH undetectable (<0.06 ng/mL), FSH persistently >40 IU/L, amenorrhea for over 6 months. The success rate of autologous IVF is extremely low (live birth rate per cycle <1%), and clinical recommendation is to evaluate donor egg IVF.
In China, both pathways have clear medical and legal frameworks, but their conditions and limitations differ significantly. These are detailed below.
II. Interpretation of Key Diagnostic Markers: What Remains of Your Ovaries
Doctors determine whether POI patients can undergo IVF and which protocol to use based primarily on the following markers:
| Marker | Reference Range (POI) | Clinical Significance |
|---|---|---|
| AMH | <1.0 ng/mL; <0.2 ng/mL suggests ovarian failure | Most stable marker of ovarian reserve, unaffected by menstrual cycle |
| FSH | >25 IU/L (two measurements >4 weeks apart) | Reflects ovarian feedback to the pituitary; higher FSH indicates lower reserve |
| LH | Often elevated with FSH; LH/FSH ratio <0.5 | Differentiates hypothalamic-pituitary amenorrhea from ovarian amenorrhea |
| E2 | Typically <50 pg/mL | Low basal E2 indicates insufficient follicular activity; elevated E2 may suggest ovarian cyst |
| Antral Follicle Count (AFC) | Total in both ovaries <5 | Direct visualization of small follicles; key basis for stimulation protocol |
| Inhibin B | <45 pg/mL | Marker of granulosa cell function; positively correlated with follicle count |
In addition to the core markers above, doctors also assess thyroid function (TSH), vitamin D, autoimmune antibodies (anti-ovarian, anti-adrenal), and karyotype to identify the etiology of POI.
III. Actual Process of IVF for POI Patients
Whether choosing autologous or donor eggs, the complete treatment process includes the following stages:
- Comprehensive etiological screening: Hormone panel + AMH + thyroid function + autoimmune antibodies + karyotype. Rule out genetic factors such as Turner syndrome mosaicism and Fragile X premutation.
- Pre-treatment and conditioning: Supplement with Vitamin D3 (2000-4000 IU/day), Coenzyme Q10 (400-600 mg/day), DHEA (for select patients, under medical guidance). Adjust BMI to 18.5-24, improve insulin resistance.
- Ovarian stimulation protocol selection: Natural cycle (no medication or only HCG trigger) or mild stimulation (Clomiphene + low-dose HMG/FSH). Conventional high-dose stimulation is not recommended due to low oocyte yield and high risk of follicular depletion.
- Oocyte retrieval and embryo culture: Transvaginal ultrasound-guided oocyte retrieval, followed by IVF or ICSI. Embryos are cultured to day 3 or day 5, and transferred or frozen based on quality.
- Embryo transfer and luteal support: Endometrial preparation using natural or artificial cycle. Progesterone + estrogen support after transfer.
For donor egg IVF, steps 3-4 (stimulation and retrieval) are omitted, proceeding directly to embryo transfer, but this requires waiting for egg donor matching, along with medical and legal evaluations for both donor and recipient.
IV. Reproductive Specialist's Perspective: Don't Give Up, But Don't Force It
As reproductive specialists, the core principle when facing POI patients is: Individualized assessment; do not conclude based on a single test result. Clinically, we have seen cases with AMH 0.1 ng/mL achieve natural pregnancy, and others with AMH 0.6 ng/mL yield empty follicles after stimulation. Therefore, we typically recommend:
- First, try 2-3 cycles of natural cycle or mild stimulation. If usable embryos are obtained, continue accumulating embryos before transfer.
- If no oocytes are retrieved for 2 consecutive cycles, or all oocytes are immature, proceed to evaluation for donor egg options.
- We advise against repeated high-dose stimulation, which increases financial burden and may accelerate ovarian depletion.
Additionally, about 10%-15% of POI patients have concurrent autoimmune thyroid disease or adrenal dysfunction. These patients require simultaneous treatment of the underlying condition, otherwise the miscarriage rate after pregnancy is higher.
V. Differences by Age Group: Dual Impact of Age and Ovarian Function
| Age Range | Feasibility of Autologous IVF | Clinical Recommendation |
|---|---|---|
| <30 years | Ovarian reserve may still fluctuate; relatively higher chance for autologous | Actively attempt natural cycle/mild stimulation; simultaneously screen for genetic factors |
| 30-35 years | If AMH ≥0.2 ng/mL, can attempt autologous; if AMH <0.2 ng/mL, consider donor egg early | Do not delay; complete evaluation and decision within 6 months of diagnosis |
| 35-40 years | Follicle quantity and quality decline simultaneously; autologous success rate significantly lower | Recommend direct evaluation for donor egg to avoid time loss |
| >40 years | Autologous live birth rate extremely low (<1%), with significantly increased risk of aneuploidy | Prioritize donor egg IVF; simultaneously assess pregnancy risks |
It should be noted that age itself is an independent factor beyond ovarian function. Even with similar AMH levels, follicle quality and embryo euploidy rates differ markedly between a 30-year-old and a 38-year-old, making age a core variable in strategy formulation.
VI. Most Easily Overlooked Details: Factors That May Affect Outcomes
In clinical practice, many POI patients focus only on AMH and FSH while neglecting the following details:
- Thyroid function: TSH >2.5 mIU/L significantly impacts follicle quality and embryo implantation; must be optimized first.
- Vitamin D levels: Serum 25-OH-VitD <30 ng/mL is associated with diminished ovarian reserve; supplementation can improve follicular sensitivity to FSH.
- Endometrial receptivity: Even with good embryos, if endometrial thickness is <7 mm or morphology is abnormal, transfer success rates drop significantly. Hysteroscopy is recommended to rule out polyps, adhesions, or chronic endometritis.
- Psychological state and sleep: Chronic anxiety and sleep deprivation can elevate cortisol, suppressing the hypothalamic-pituitary-ovarian axis and further worsening ovarian suppression.
Although these details are not directly part of "IVF technology," they are often key variables determining cycle success or failure.
VII. Common Pitfalls: Avoid These Frequent Mistakes
Pitfall 1: Blindly pursuing high-dose stimulation. POI patients have very low follicular reserve; high-dose stimulation does not increase oocyte yield but may accelerate follicular depletion and even cause pseudo-Ovarian Hyperstimulation Syndrome (OHSS).
Pitfall 2: Starting a cycle without etiological screening. If a patient has autoimmune oophoritis, thyroid dysfunction, or chromosomal abnormalities, proceeding directly to a cycle often ends in failure, wasting time and money.
Pitfall 3: Unrealistic expectations for donor egg IVF. Donor egg IVF significantly increases pregnancy rates, but risks of miscarriage, ectopic pregnancy, etc., remain. Additionally, waiting time for egg donation is unpredictable (average 12-36 months in China), requiring proper planning.
Pitfall 4: Not adjusting the protocol after repeated implantation failure. If the same protocol fails after 3 or more attempts, re-evaluate endometrial receptivity, embryo genetics, and maternal immune factors, rather than simply attributing it to "bad luck."
VIII. Special Situations: Differentiated Strategies by Etiology
Premature Ovarian Insufficiency is not a single disease; management varies by cause:
- Autoimmune oophoritis: Accounts for 10%-20% of POI. Requires concurrent immunomodulation (e.g., glucocorticoids) and antioxidant therapy, but must be coordinated between rheumatology and reproductive medicine to avoid infection risk.
- Ovarian failure post-chemotherapy/radiotherapy: For patients wishing to preserve fertility, oocyte cryopreservation or ovarian tissue freezing should be completed before treatment. If failure has already occurred, donor egg IVF is the primary option.
- Turner syndrome mosaicism: Some mosaic patients still have follicles, but cardiovascular risk during pregnancy is high. Cardiac ultrasound and aortic assessment are required before confirming safety for pregnancy.
- Idiopathic POI: For patients without identifiable cause after excluding known etiologies, the core treatment principle is "buying time"—complete fertility assessment and decision-making promptly.
In special cases, doctors may suggest adjunctive therapies like growth hormone (GH) or androgens (e.g., DHEA), but current evidence is limited; these should be pursued in clinical trials or experienced centers.
Doctor's Advice
If you are reading this article and have been diagnosed with Premature Ovarian Insufficiency, here are clear recommendations:
- Do not give up on yourself—POI does not mean 100% infertility. First, complete a comprehensive etiological screening and ovarian reserve assessment.
- Do not wait indefinitely—Ovarian function will only continue to decline with age and disease progression. Aim to make a decision within 6 months of diagnosis.
- Choose a reproductive center experienced with POI—Proficiency with mild stimulation protocols and natural cycle embryo accumulation strategies varies significantly between centers. Research thoroughly before deciding.
- Protect your endometrium—Regardless of the path chosen, the endometrium is the foundation for embryo implantation. Avoid repeated uterine procedures and unnecessary curettage.
All treatment plans should be carried out under the guidance of a reproductive specialist. This content is for educational purposes only and does not replace individualized medical decisions.
When to get tested for premature ovarian insufficiency How far in advance to prepare for overseas IVF Can I still do overseas IVF with low AMH What to prepare for IVF at advanced age Do I need to prepare before IVF for premature ovarian insufficiency How to do IVF with high FSH What are the requirements for donor egg IVF Is egg donation legal in China Natural cycle protocol for POI Mild stimulation ovulation induction
Comments (0)